1.69
+0.02(+1.20%)
Currency In USD
| Previous Close | 1.67 |
| Open | 1.69 |
| Day High | 1.76 |
| Day Low | 1.66 |
| 52-Week High | 4.92 |
| 52-Week Low | 1.23 |
| Volume | 225,080 |
| Average Volume | 638,587 |
| Market Cap | 63.45M |
| PE | -0.71 |
| EPS | -2.39 |
| Moving Average 50 Days | 2.39 |
| Moving Average 200 Days | 1.96 |
| Change | 0.02 |
If you invested $1000 in Metagenomi, Inc. Common Stock (MGX) since IPO date, it would be worth $163.92 as of November 27, 2025 at a share price of $1.69. Whereas If you bought $1000 worth of Metagenomi, Inc. Common Stock (MGX) shares 1 year ago, it would be worth $163.92 as of November 27, 2025 at a share price of $1.69.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Metagenomi to Present at Jefferies Global Healthcare Conference in London
GlobeNewswire Inc.
Nov 17, 2025 1:00 PM GMT
EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced
Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development
GlobeNewswire Inc.
Nov 11, 2025 9:01 PM GMT
MGX-001 demonstrated curative FVIII activity in non-human primates Pre-IND regulatory meeting expected in Q4 2025 with investigational new drug (IND) and clinical trial application (CTA) submissions expected in 4Q 2026 EMERYVILLE, Calif., Nov. 11,
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors
GlobeNewswire Inc.
Aug 11, 2025 8:05 PM GMT
Dr. Reid brings 30 years of experience in building biotech companies based on innovative scientific platforms and shaping pipeline and business strategyEMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Compa